MedTrace Logo

Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma

NCT01395420 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-09-01

No results posted yet for this study

Summary

This is an open-label study divided in 2 parts and 3 cohorts to determine the concentration of Avibactam and Ceftazidime in the lining of the lungs and the blood.

Conditions

  • Healthy

Interventions

DRUG

CAZ104

IV Infusion

DRUG

CAZ104

IV Infusion

Sponsors & Collaborators

Principal Investigators

  • Paul Newell, MD · AstraZeneca

  • Leonard Siew, MBCHB, MRCP(UK) · Quintiles Phase I unit London

  • Mirjana Kujacic, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01395420 on ClinicalTrials.gov